GLP-1s Going Under-Covered

U.S. healthcare expenditure on GLP-1 medications surged beyond $50 billion in 2023, yet only 25% of employers currently cover GLP-1s for weight management. Employers are now at the forefront of a challenging healthcare decision- to cover or not to cover? They have to weigh happy and healthier employees with comprehensive health benefits and maintaining financial viability as a company. A true rock and a hard place. In response to this dilemma, new approaches to cost-management are being explored, including value-based pricing negotiations, implementing targeted patient assistance programs, and integration of comprehensive wraparound services to maintain treatment efficacy. Employers are having to go deep into long-term safety assessments and coverage decisions through risk analytics, while simultaneously shifting towards proactive, preventative weight management approaches. A balanced approach may just be the way out of this difficult dilemma.